Synageva offering LSD patients renewed hope
Authored by James Sheppard As part of Liftstream’s commitment to rare diseases, in the run up to Rare Disease Day 2013 we will be profiling 10 companies that are leading the rare disease research...
View ArticlePTC Therapeutics opts for conditional approach in Duchenne
Authored by Paul Foster As part of Liftstream’s commitment to rare diseases, in the run up to Rare Disease Day 2013 we will be profiling 10 companies that are leading rare disease research. In the...
View ArticleDavid Motts’ NEA weighs in on rare diseases
Authored by Karl Simpson David Mott is a man who is used to making a difference to the life sciences landscape. The ex-CEO of MedImmune was instrumental in selling the company to AstraZeneca for...
View ArticleMassachusetts biotech continues to excite with new investments
Authored by Karl Simpson Massachusetts is a booming biotech cluster and this week has seen a number of funding events that once again signal the level of innovation and investor interest the cluster...
View ArticleNovartis scores FDA breakthrough-designation for rare disease product
Authored by Karl Simpson Breakthrough Therapy designation has been given by the FDA to Novartis for their development asset , which is an orphan drug being developed to treat patients with sporadic...
View ArticleSwedish Pharmalink receives Orphan Drug Approval for Busulipo
Authored by James Sheppard The Swedish speciality pharmaceutical company Pharmalink AB announced that it had received Orphan Drug approval from the US FDA for oncology conditioning agent Busulipo....
View ArticleKiadis rides high after positive clinical data
Authored by James Sheppard The Dutch biotechnology company Kiadis Pharma is continuing on its positive trajectory following the release of positive phase II clinical update for lead asset ATIR. Initial...
View ArticleMerck announces collaboration with Advaxis
Authored by James Sheppard The global pharmaceutical giant Merck & Co announced it had partnered with the New Jersey based biotech company Advaxis. The collaboration will see the pair test...
View ArticleM&A Continues to Dominate the Rare Diseases Landscape
Alexion took everyone by surprise in recent weeks by announcing a very sizable acquisition of Boston-based Synageva for $8.4bn. This was a significant deal which will only serve to strengthen...
View ArticleSanofi Genzyme Bioventures announce a brace of deals
Sanofi Genzyme Bioventures announced to financing deals today (Sept 8 – 2015), as it contributed to the financing of Proteostasis Therapeutics, a Series B mezzanine round of $37m to the company...
View Article
